AQST Rasio cepet Aquestive Therapeutics

The daily price chart for Aquestive Therapeutics (AQST) is driven by the implementation of unique oral films that extend drug efficacy and build a loyal customer base. The current metric stands at 6.82. The business is countering pressure from traditional drug formats and the risk of patent expiration. The company's stability relies on the approval of new products for the treatment of epilepsy and allergies, as well as incoming royalties.

This indicator assesses the ability of Aquestive Therapeutics (AQST) to instantaneously settle short-term liabilities using exclusively cash and accounts receivable, excluding slow-moving inventories. By analyzing the quick ratio, an investor determines the financial stability of Aquestive Therapeutics (AQST), where high solvency is critical for scaling the production of therapeutic films and reducing unit costs as output volumes increase.